Fundraising FoxOphthotech
New York, US · Delaware corporation · 4 known investors
Find your way into Ophthotech
Sign up to see every warm intro you have to Ophthotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ophthotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DG
David GuyerFounder
GS
Glenn SblendorioExecutive
MA
Mike AtiehExecutive Vice President, Chief Financial and Business Officer2014–2016Mike Atieh was Executive Vice President and Chief Financial and Business Officer at Ophthotech through 2016, and previously held CFO positions at OSI Pharmaceuticals and Eyetech, which was acquired by Valeant Pharmaceuticals in 2012. Earlier in his career, he spent 20 years at Merck in executive roles spanning human health, managed care, government relations, and treasury, and began his career as an audit manager at Arthur Young.
DR
David RedlickNamed on SEC filing
KW
Keith WestbyNamed on SEC filing
DC
David CarrollNamed on SEC filing
TD
Thomas DyrbergNamed on SEC filing
AB
Axel BolteNamed on SEC filing
JP
Jane Pritchett HendersonNamed on SEC filing
Board
MR
Investors · 4
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M
How we know: SV Health Investors's portfolio page · Not right? Tell us
Clarus VenturesreportedMenlo Park
How we know: funding news · biospace.com · Not right? Tell us
SV Life SciencesreportedBoston
How we know: funding news · biospace.com · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$11.4M disclosed across 1 round · 2018
▶$11.4MraisedNov 2018 · 2 investors · BiotechnologyRule 506(b)
▶$11.4MraisedNov 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David RedlickDirector
- Michael RossDirector
- Keith WestbyExecutive Officer
- David CarrollExecutive Officer
- Thomas DyrbergDirector
- Glenn SblendorioExecutive Officer, Director
- Axel BolteDirector
- Jane Pritchett HendersonDirector
- David GuyerExecutive Officer, Director
- Offering amount
- $11.7M
- Amount sold
- $11.4M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
VedantuVedantu is an online learning platform that provides free chapter-wise NCERT solutions and study materials for Class 12 CBSE students across Science, Commerce, and Arts subjects. It also offers resources for competitive exam preparation such as JEE and NEET, aligned with the latest CBSE syllabus.
AMDAMD designs the Ryzen and EPYC processors, Radeon graphics and Instinct AI accelerators, and the adaptive chips it added with the Xilinx acquisition. Founded in Santa Clara in 1969, it is listed on Nasdaq as AMD.
Companies working in the same space as Ophthotech.
In the news
Frequently asked questions
- Who founded Ophthotech?
- Ophthotech was founded by David Guyer.
- Who are Ophthotech's investors?
- Ophthotech's investors include Sofinnova Ventures, SV Health Investors, Clarus Ventures, SV Life Sciences.
- How much funding has Ophthotech raised?
- Ophthotech has disclosed $11.4M raised across 1 round.
- Where is Ophthotech headquartered?
- Ophthotech is headquartered in New York, US.